Private evidence brief · China · Guangzhou location check

Minimally Invasive Electro-Septal Myectomy (MESM)

Guangzhou: UNESTABLISHED · Documented city: Hangzhou

MESM expands to minimally invasive electro septal myectomy.[1]

The MESM programme page names Zhejiang Provincial People’s Hospital in Hangzhou, China.[1]

This review documents one MESM centre worldwide, which is a documented-centre count rather than a market total.[1]

Names readers may encounter

  • Chinese professional reporting pairs 微创室间隔电切术 with MESM.[6]
  • In the MESM literature, minimally invasive septal myectomy uses sternum-sparing right infra-axillary access rather than a catheter-only route.[2]
  • Transaortic septal myectomy via right infra-axillary incision is the title terminology of the 148-patient cohort.[2]
  • The MESM programme describes the operation as a modified transaortic Morrow procedure.[1]
  • 微创Morrow术 appears as Chinese shorthand on a public physician profile.[7]
  • Classical septal myectomy removes thickened septal muscle during open-heart surgery to relieve obstruction.[8]
  • Alcohol septal ablation is a catheter-based septal-reduction procedure rather than MESM.[5]

Procedure explanation

Generated procedure diagram from cited operative descriptions

MESM is described as a modified Morrow procedure performed through a five-centimetre right infra-axillary incision in the third intercostal space with electrocautery.[1]

Right infra-axillary access
Cardiopulmonary bypass and cardiac arrest
Transaortic septal exposure
Electrocautery-assisted resection

Candidacy boundaries

The 100-patient MESM cohort enrolled people with symptomatic hypertrophic obstructive cardiomyopathy that remained refractory to medical therapy.[3]

The AHA and ACC guideline says septal-reduction therapy must be performed at experienced hypertrophic-cardiomyopathy centres.[4]

The guideline says septal-reduction therapy should not be performed in asymptomatic patients with normal exercise capacity.[9]

The MESM programme asks for transthoracic echocardiography with gradients and systolic-anterior-motion assessment, cardiac CT or MRI when available, and a clinical summary with current medication.[1]
COMPARISON_TABLE

Five-option comparison

Option Who it suits Evidence Key risks Reversibility What changes the decision
Full sternotomy myectomy Associated cardiac disease needing surgery C48 Established surgical route at experienced centres C27, C33 UNESTABLISHED here UNESTABLISHED Need for concomitant cardiac surgery C48
MESM Study population: symptomatic obstructive HCM refractory to medication C32 Single-centre retrospective cohorts C37–C41 Pacemaker implantation and reported in-hospital death C42, C43 UNESTABLISHED Sternum-sparing access weighed against absent randomised comparison C31, C46
Alcohol septal ablation Eligible patients when surgery is contraindicated C48 Guideline-recognised catheter route C28, C48 Targeted myocardial cell death C49 UNESTABLISHED Surgical contraindication C48
Medical therapy including myosin inhibitors Clinician-directed stepwise therapy C47 Guideline pathway C47 UNESTABLISHED here UNESTABLISHED Persistence of symptoms after medication trials C47
Postponement / no intervention Asymptomatic with normal exercise capacity C34 Monitoring and non-intervention boundary C34, C36A, C36B Disease progression remains possible C50 UNESTABLISHED Symptoms, exercise capacity, imaging or rhythm findings change

Evidence and overlap

The 148-patient series enrolled consecutive patients treated from September 2021 through July 2023 at one centre.[2]

Funding: UNESTABLISHED in the checked display.

Conflicts: UNESTABLISHED in the checked display.

The 100-patient series enrolled consecutive patients treated from November 2023 through May 2024 at one centre.[3]

PubMed lists Zhejiang provincial research support for the 100-patient paper and reports that its authors disclosed no conflicts of interest.[3]

The reported enrolment windows do not overlap, so the two cohorts are independent by patient dates but not independent external confirmation.[10]

Shared authors: Shuwei Wang, Zhiqiang Dong, Zhifang Liu, Erlei Han, Changhao Wu, Chentao Luo, Weikang Chen, Fuyang Mei, Xiaofeng Lu, Meijuan Yan, Zhenzhen Wang, Bing Zhou and Yong Cui.

Generated data pattern from the cited 100-patient cohort

The 100-patient cohort reported a mean left-ventricular-outflow-tract gradient change from 85.8 to 8.4 millimetres of mercury after surgery.[3]

Before

85.8 mm Hg
After

8.4 mm Hg

Study-cohort pattern only; not a personal forecast.

Material risks

In the 148-patient cohort, eight patients received permanent pacemakers and one patient died in hospital after an intraoperative subarachnoid haemorrhage.[2]

In the 100-patient cohort, four patients received permanent pacemakers, while no in-hospital death or iatrogenic ventricular-septal defect was reported.[3]

Randomised comparisons of MESM against sternotomy myectomy have not been performed.[1]

Recovery and follow-up

Structured recovery path from cited cohort and guideline facts
In-hospital recovery
Discharge planning
Imaging and rhythm review
Long-term HCM surveillance

The 148-patient study reported a mean hospital stay of 9.7 days with a standard deviation of 4.9 days.[2]

The 148-patient report described only early results and called for continued long-term follow-up.[10]

The guideline recommends repeating transthoracic echocardiography every one to two years or sooner when clinical status changes.[4]

The guideline includes a twelve-lead electrocardiogram in initial and annual follow-up and recommends twenty-four to forty-eight hours of ambulatory monitoring.[4]

Alternatives and postponement

The guideline places beta-blockers first and lists myosin inhibitors, disopyramide, or septal-reduction therapy when symptoms persist after medication trials.[4]

The guideline recommends surgical myectomy when associated cardiac disease also requires surgery and allows alcohol septal ablation when surgery is contraindicated.[4]

Alcohol septal ablation uses ethanol to make the targeted septal cells die and the thickened tissue shrink.[5]

Hypertrophic cardiomyopathy can worsen over time and may lead to atrial fibrillation, stroke, heart failure, or sudden cardiac arrest.[5]

Clinic dossier

Location and programme

Country: China

Documented city: Hangzhou

Guangzhou: UNESTABLISHED

Documented centres worldwide: 1 documented centre; not a market total.

Bookimed relationship: NO PUBLIC RELATIONSHIP FOUND

Eligibility packet

  • Recent transthoracic echocardiography with gradients and SAM assessment
  • Cardiac CT or MRI where available
  • Clinical summary
  • Current medication list

The guideline recommends coronary angiography before septal-reduction therapy.[4]

Aftercare and access

Aftercare/rescue owner: UNVERIFIED

International intake: UNVERIFIED

Languages: UNVERIFIED

Expected local stay: UNVERIFIED

Cross-border follow-up: UNVERIFIED

Bounded team

Identification portrait of cardiac surgeon Yong Cui
This identification portrait is presented on a public article attributed to cardiac surgeon Yong Cui.[12]
Source: 心脏外科崔勇医生 via Sohu

Yong Cui, MD, PhD

PubMed affiliates Yong Cui with the Heart Center and Department of Cardiovascular Surgery at Zhejiang Provincial People’s Hospital in Hangzhou.[3]

A professional training report states that Yong Cui demonstrated MESM during live surgical teaching.[11]

The MESM programme names Yong Cui as its cardiac surgeon and technique creator.[1]

PERSONALLY_OPERATING D3 Access UNVERIFIED

Zhenzhen Wang, MD

The MESM programme names Wang Zhenzhen in echocardiography and diagnosis.[1]

CENTRE_PARTICIPATION D1

Meijuan Yan, MD

The MESM programme names Yan Meijuan in anaesthesia and ultra-fast-track care.[1]

CENTRE_PARTICIPATION D1

CHECKLIST

Records and questions

  • Bring the complete echocardiography files, not only a written summary.
  • Add cardiac CT or MRI when available.
  • List current and previously tried medicines.
  • Ask which anatomy drives the obstruction.
  • Request the named operator and accountable perioperative team.
  • Ask for centre-specific contemporary outcomes.
  • Agree who owns routine follow-up, urgent complications and records transfer.
FAQ

FAQ by procedure name

What does MESM mean?

MESM means minimally invasive electro septal myectomy.[1]

What is Minimally Invasive Electro-Septal Myectomy?

Minimally Invasive Electro-Septal Myectomy is a transaortic surgical myectomy using right infra-axillary access and electrocautery-assisted resection.[3]

What does minimally invasive septal myectomy mean here?

Here, minimally invasive septal myectomy means sternum-sparing access through the right infra-axillary chest wall.[2]

What is transaortic septal myectomy via right infra-axillary incision?

It is the predecessor cohort’s title term for the same access route later labelled MESM.[2]

Is MESM a modified Morrow procedure?

The programme describes MESM as a modified transaortic Morrow procedure.[1]

What does 微创室间隔电切术 refer to?

微创室间隔电切术 is the documented Chinese name paired with MESM.[6]

What does 微创Morrow术 mean?

微创Morrow术 is Chinese shorthand used for minimally invasive Morrow surgery.[7]

What is surgical septal myectomy or the Morrow operation?

Classical surgical septal myectomy removes obstructing septal muscle during open-heart surgery.[8]

Is alcohol septal ablation the same as MESM?

Alcohol septal ablation is a distinct catheter-based procedure.[5]

Trust and review status

Review date: 30 August 2026

Last guideline check: 30 August 2026

Last regulator check: 30 August 2026

Clinical reviewer: NOT_ASSIGNED · human review task open

Sources

  1. MESM programme, technique, team and referral requirements
  2. JTCVS Techniques cohort
  3. PubMed MESM cohort record
  4. ACC HCM guideline key points
  5. American Heart Association HCM overview
  6. Chinese MESM terminology report
  7. Chinese physician profile
  8. Cleveland Clinic septal myectomy overview
  9. AHA/ACC guideline slide deck
  10. Publisher cohort page and limitations
  11. Professional training report
  12. Public portrait source

How this guide was prepared

Prepared by: bookimed_ai — Automated research and publishing account.

Bookimed medical governance contact: Fahad Mawlood — Medical Editor & Data Scientist. See the linked profile for role details. This identifies an organization-level role and does not mean this person personally reviewed this page.

Last updated . See Bookimed’s editorial policy and Medical Advisory Board.